Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.

作者信息

Enz A, Boddeke H, Gray J, Spiegel R

机构信息

Preclinical Research CNS Department, Sandoz Pharma Ltd., Basle, Switzerland.

出版信息

Ann N Y Acad Sci. 1991;640:272-5. doi: 10.1111/j.1749-6632.1991.tb00232.x.

DOI:10.1111/j.1749-6632.1991.tb00232.x

PMID:1776750

Abstract

摘要

相似文献

Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.

Ann N Y Acad Sci. 1991;640:272-5. doi: 10.1111/j.1749-6632.1991.tb00232.x.

Rivastigmine: a review.

Hosp Med. 1999 Oct;60(10):731-5. doi: 10.12968/hosp.1999.60.10.1217.

Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.

Prog Brain Res. 1993;98:431-8. doi: 10.1016/s0079-6123(08)62429-2.

[Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].

Med Monatsschr Pharm. 1998 Aug;21(8):248-9.

Brief review: rivastigmine, a second cholinesterase inhibitor.

Can J Neurol Sci. 2001 Feb;28 Suppl 1:S122-3. doi: 10.1017/s0317167100001293.

Surprising discovery with Alzheimer's medication.

Drug Discov Today. 2003 May 1;8(9):379-80. doi: 10.1016/s1359-6446(03)02685-0.

Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?

Int J Clin Pract. 2002 Jul-Aug;56(6):414-5.

Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease.

Eur J Med Chem. 2002 Feb;37(2):91-109. doi: 10.1016/s0223-5234(01)01324-1.

FDA approves new cholinesterase inhibitor for Alzheimer's disease.

Am J Health Syst Pharm. 2000 Jun 1;57(11):1026, 1028. doi: 10.1093/ajhp/57.11.1026.

[New perspectives for Alzheimer patients: acetylcholine inhibition with Rivastigmine. Congress of the European Neurologic Society. Nice, 6 July 199].

Dtsch Med Wochenschr. 1998 Nov 27;123(48 Suppl):1-4.

引用本文的文献

Decarbamoylation of acetylcholinesterases is markedly slowed as carbamoyl groups increase in size.

Arch Biochem Biophys. 2018 Oct 1;655:67-74. doi: 10.1016/j.abb.2018.08.006. Epub 2018 Aug 9.

Characterization of the interactions between coumarin-derivatives and acetylcholinesterase: Examination by NMR and docking simulations.

J Mol Model. 2018 Jul 14;24(8):207. doi: 10.1007/s00894-018-3751-3.

Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

Curr Ther Res Clin Exp. 2003 Apr;64(4):216-35. doi: 10.1016/S0011-393X(03)00059-6.

Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.

Clin Pharmacokinet. 2013 Apr;52(4):225-41. doi: 10.1007/s40262-013-0038-9.

Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.

CNS Neurosci Ther. 2010 Spring;16(1):51-60. doi: 10.1111/j.1755-5949.2009.00119.x.

Rivastigmine for the treatment of dementia associated with Parkinson's disease.

Neuropsychiatr Dis Treat. 2007 Dec;3(6):775-83. doi: 10.2147/ndt.s1134.

Investigation of the binding mode of (-)-meptazinol and bis-meptazinol derivatives on acetylcholinesterase using a molecular docking method.

J Mol Model. 2006 Mar;12(4):390-7. doi: 10.1007/s00894-005-0058-y. Epub 2006 Jan 11.

Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression.

Emerg Med J. 2006 Jan;23(1):82-5. doi: 10.1136/emj.2004.017301.

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.

J Psychiatry Neurosci. 2003 Jan;28(1):13-26.

Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors.

J Comput Aided Mol Des. 2001 May;15(5):395-410. doi: 10.1023/a:1011150215288.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验